Last reviewed 2026-04-22 · How we verify

AK104(SC)

AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.

AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses. Used for Advanced non-small cell lung cancer, Advanced hepatocellular carcinoma, Other advanced solid tumors.

At a glance

Mechanism of action

AK104 functions as a PD-1/TIM-3 bispecific antibody that blocks two inhibitory checkpoints on T cells, thereby relieving immune suppression in the tumor microenvironment. By targeting both PD-1 and TIM-3, the drug aims to overcome resistance to single-checkpoint inhibition and restore robust anti-tumor immunity. This dual-checkpoint approach is designed to improve efficacy in patients with advanced solid tumors.

Approved indications

• Advanced non-small cell lung cancer
• Advanced hepatocellular carcinoma
• Other advanced solid tumors

Common side effects

• Fatigue
• Nausea
• Decreased appetite
• Immune-related adverse events (pneumonitis, hepatitis, colitis)

Key clinical trials

• A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.